ABCB1 p.Lys536Gln
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 15212152
[PubMed]
Pauli-Magnus C et al: "Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)."
No.
Sentence
Comment
118
Functional Impact in vitro of MDR1 Variants Amino acid change Functional effect of the variant allele Reference Val185Ser Increased colchicine resistance [30] ⌬Phe335 Decreased resistance to vinca alkaloids; no resistance to dactinomycin [31] Lys536Gln, Gly534Asp, Lys536Arg, Ser532Arg, ⌬Tyr490 Defective RNA processing [33] Ala893Ser Acquired overexpression of one allele in drug-resistant cells [20] Ala893Ser Decreased digoxin efflux [19] Asn21Asp, Phe103Leu, Ser400Ala, Ala893Ser, Ala893Thr No effect on P-glycoprotein cell surface expression and substrate specificity [69] Ala893Ser No difference in calcein-AM transport [27] Ala893Ser/Thr No difference in transport of verapamil, digoxin, viblastine and cyclosporine A [35] 3435 polymorphisms were analyzed separately, with AUC values being highest for individuals carrying the reference alleles.
X
ABCB1 p.Lys536Gln 15212152:118:250
status: NEW
PMID: 7914197
[PubMed]
Hoof T et al: "Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1."
No.
Sentence
Comment
110
MRK16 recognizes external epitopes of human MDRl without cross-reactions with rodent P-glycoproteins (Hamada and Tsuruo, 1991).The AY490 and AY490-K536Q transfectants were negative for MRK16 like the parentcontrol line CHO K1 (Fig. 4A).In the S532R and G534D MDRls recombinant cell lines, mixed populations of MRK16 immunoreactive cells were observed (Fig. 4A).Subsequentexposure to colchicine(100,125, 150,or 175ng/ml) increased the proportion of cells with higher antigen density with increasing colchicine concentration (Fig. 4B).
X
ABCB1 p.Lys536Gln 7914197:110:147
status: NEW112 Homogeneous populations of human P-glycoprotein-expressing cells were observed in thecelllines thatwere carryingwild-type MDRl, K536R MDR1, or K536Q MDRl cDNA (Fig. 4A).
X
ABCB1 p.Lys536Gln 7914197:112:143
status: NEW113 Phenotype of Multidrug Resistance and Collateral Sensitiuity-Transfection withMDRl vector constructsren- AY490 G534D K536Q 1 ".
X
ABCB1 p.Lys536Gln 7914197:113:117
status: NEW116 1 , ', k. ,-I wt S532R K536R AY490 I K536Q transcripts in recombinant CHO K1 cells by RTPCR kinetics.
X
ABCB1 p.Lys536Gln 7914197:116:37
status: NEW122 dered the CHO K1 cells more resistant toadriamycin and colchicine when either wild-type sequence or the codon 536 variants, K536R or K536Q, had beenintroduced(Fig.2).This finding on the G418-preselected cell pool was confirmed by growth inhibitionexperiments withclonal cell lines.
X
ABCB1 p.Lys536Gln 7914197:122:133
status: NEW130 Cell line Fluorescence Signalnormalized to CHO K1 control CHO K1 8.6 x 10' CHO K1 (MDR1) 1.0 CHO K1 (AY490 MDR1) 6.3 x 10' 0.7 CHO K1 (S532R MDR1)" 4.4 x 104 51 CHO K1 (G534D MDR1)" 2.1 x 105 240 CHO K1 (K536R MDR1) 5.6 x 105 650 CHO K1 (K536Q MDR1) 9.4 x 105 CHO K1 (AY490-K536QMDR1) 2.1 x lo3 1,100 6.5 x 105 750 2.4 a The datarefer to the MRK16-positive subpopulation.
X
ABCB1 p.Lys536Gln 7914197:130:238
status: NEW141 The strongly photoreactive band of P-glycoprotein was exclusively seeninplasmamembranes from cells exhibiting the multidrug resistance phenotype, i.e. transfectants MDRls K1, K536Q MDRls K1, K536R MDRls K1(Fig. 6, left lane in eachpanel), and theB30 positive control.
X
ABCB1 p.Lys536Gln 7914197:141:175
status: NEW147 Opentriangles, wild-type MDRls CHO K1; closed cycles, K536R MDRls K1; closed triangles, K536Q MDRls K1; stars, S532R MDRls K1; opencircles, AY490 MDRls K1; closed squares, G534D MDRls K1; bars, AY490-K536QMDRls K1; open squares,CHO K1.
X
ABCB1 p.Lys536Gln 7914197:147:88
status: NEW148 TABLE111 Multidrug resistance and chemosensitizationof P-glycoprotein-expressingCHO cell clones Cell line ID,, values 0 prt' 1 p!.t" 3PMc" 10PMO nglml Colchicine CHO K1 54 6/13 3/13 5'18 CHO K1 (MDR1) 530 1901320 121110 2'/40 ' CHO K1 (K536Q MDR1) 18015/56 6/26 5'113' CHO K1 (K536R MDR1) 840 4801680 471140 7'1546 Vinblastine CHO K1 12 213 112 1'11 CHO K1 (MDR1) 240 1001180 10170 2'I8 ' CHO K1 (K536Q MDR1) 150 10148 3/14 2'I3 ' CHO K1 (K536R MDR1) 220180/210 15190 2'17 ' CHO K1 18 314 314 3'I3 CHO K1 (MDR1) 280100/230 8170 4'114 CHO K1 (K536Q MDR1) 60 6116 317 3'13' CHO K1 (K536R MDR1) 350 190/270 17/70 3'Ill ' a Concentration of cyclosporin (lefi)/FK506 (right).
X
ABCB1 p.Lys536Gln 7914197:148:236
status: NEWX
ABCB1 p.Lys536Gln 7914197:148:397
status: NEWX
ABCB1 p.Lys536Gln 7914197:148:542
status: NEW175 MDR1" Wildt w e AY490 S532RG534D AY490-K536Q K536Q.
X
ABCB1 p.Lys536Gln 7914197:175:39
status: NEW
PMID: 9169612
[PubMed]
Bakos E et al: "Characterization of the human multidrug resistance protein containing mutations in the ATP-binding cassette signature region."
No.
Sentence
Comment
26
The mutant K536Q (Lys to Gln) was expressed in comparable amounts to the wild-type protein, but conferred decreased drug resistance, while the K536R (Lys to Arg) replacement increased multidrug resistance, with a preferential resistance to colchicine.
X
ABCB1 p.Lys536Gln 9169612:26:11
status: NEW
PMID: 16352426
[PubMed]
Ambudkar SV et al: "The power of the pump: mechanisms of action of P-glycoprotein (ABCB1)."
No.
Sentence
Comment
52
Between the Walker A and B sequences is found a linker peptide with the sequence LSGGQ, also known as the C-region or ABC signature sequence, as it is the hallmark of Table 1 - Summary of mutational analysis of conserved residues in nucleotide-binding domains of Pgp Domain Source Residue number Function Reference NBD1 NBD2 A-loop Human Y401A Y1044A No ATP binding/hydrolysis Kim et al. (submitted for publication) Walker A Mouse K429N K1072N Normal ATP binding but no hydrolysis Azzaria et al. (1989) G431A G1073A Human C431 C1074 ATP protects from modification by N-ethylmaleimide Loo and Clarke (1995) Disulfide bond formation between Walker A domains of both NBDs Urbatsch et al. (2001) Human K433M K1076M Decreased ATP-binding Muller et al. (1996) No ATP hydrolysis Szakacs et al. (2000) No vanadate-trapping, but aluminum and beryllium fluoride-induced trapping normal Q-loop Mouse Q471 Q1114 Not essential for ATP hydrolysis but may be involved in communication with drug-substrate sites Urbatsch et al. (2000a) LSGGQ or linker peptide or signature motif Mouse S528A S1173A Normal ATP binding but no hydrolysis Tombline et al. (2004a) Human S532R Decreased cell surface expression Hoof et al. (1994) Human G534C G1179C No ATP hydrolysis Loo et al. (2002) Human G534D Decreased cell surface expression Hoof et al. (1994) No drug resistance Normal cell surface expression Bakos et al. (1997) No ATP hydrolysis Human G534D/V G1179D Interdomain communication Szakacs et al. (2001) Human Q535C Q1180C No ATP hydrolysis Loo et al. (2002) Human K536Q Decreased drug resistance Hoof et al. (1994) LSGGQ or linker peptide or signature motif Human K536R Increased colchicine resistance (normal ATP hydrolysis?)
X
ABCB1 p.Lys536Gln 16352426:52:1548
status: NEW